ClinicalTrials.gg
RecruitingNCT05955924SPRINTRUpdated Oct 13, 2026

Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial

A Phase 3 interventional study of Nicotinamide and Placebo in Non-melanoma Skin Cancer, Carcinoma, Squamous Cell and Carcinoma, Basal Cell, sponsored by Women's College Hospital. Recruiting at 7 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Women's College Hospital · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Carcinoma, Squamous Cell with a site in Canada — 5 open to participants now, 9 under way, 4 of them phase 3. Carcinoma, Squamous Cell · Canada.

Planned enrollment
11th of 42
396 · median 112
Started
2023
the only one that year
Phase 3
12 of 45
3 open now
Registered
41st of 45
by date
Lead sponsor
2 of 45
Women's College Hospital

Among the 45 studies in Carcinoma, Squamous Cell with a site in Canada, this one is the 11th largest by planned enrollment of the 42 interventional ones that give a count, is the only one that started in 2023, is one of 12 in phase 3, and was the 41st registered.

Carcinoma, Squamous Cell

629 studies on the registry are indexed under Carcinoma, Squamous Cell; 135 are open to participants now.

Browse Carcinoma, Squamous Cell studies →

Open to participants now

5 of the 45 studies in Carcinoma, Squamous Cell with a site in Canada are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 102 Carcinoma, Squamous Cell studies recruiting now, 86 (84%) set no upper age limit and 8 (8%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Carcinoma, Squamous Cell with a site in Canada, or all of them as a file.
02

Study summary

As patients live longer after receiving an organ transplant, there is a need to reduce the long-term side effects of the drugs used to prevent organ rejection. In particular, long-term use of these drugs increases the risk of skin cancer. Skin cancer is now a leading cause of illness and disfigurement after kidney, liver, heart, and lung transplantation. Given the increased risk and burden of skin cancer in transplant recipients, prevention is critical.

Nicotinamide is a form of Vitamin B3 that has been shown to protect against skin cancer in the general population. However, it is unclear whether nicotinamide is effective among immune-suppressed transplant recipients. Investigators will conduct a clinical trial involving multiple transplant centres in Canada to evaluate whether oral nicotinamide (500 mg twice daily) is effective and safe for preventing skin cancer. Investigators will recruit 396 high-risk adult kidney, liver, heart, and lung transplant patients who have previously had at least one skin cancer. Patients will receive nicotinamide or sham tablets for up to 4 years. The results will inform efforts to improve the long-term health of transplant recipients.

Read the detailed description

Improved survival after solid organ transplantation has created the need to better prevent the long-term adverse effects of immunosuppressant drugs in transplant survivors - particularly cancer development. Keratinocyte carcinoma (non-melanoma skin cancer) is by far the most common form of post-transplant malignancy and has a more aggressive clinical course than in the general population. Preventive measures are thus critical to reduce the burden of skin cancer in the high-risk transplant population.

Nicotinamide is a low-cost, commercially available, over-the-counter Vitamin B3 derivative that has been found to safely reduce the rate of keratinocyte carcinoma in immunocompetent patients with a history of skin cancer. It is unclear whether its efficacy and safety translate to the immunosuppressed transplant population.

Given this uncertainty, Investigators plan to build on our internal pilot study (N=120) to conduct the SPRINTR (Skin cancer PRevention with Nicotinamide in Transplant Recipients) pivotal trial to address these specific aims:

Primary question: Does oral nicotinamide (500 mg twice daily) reduce the rate of further keratinocyte carcinoma compared with placebo when used in addition to standard care for up to 208 weeks in high-risk solid organ transplant recipients?

Secondary questions:

  1. What is the safety of nicotinamide when used in addition to standard care for up to 208 weeks in the transplant population?
  2. What is the effect of nicotinamide on quality of life related to skin cancer?

Investigators will conduct a multicentre, pragmatic, parallel group, investigator- and patient-blinded, randomized trial with a superiority framework. This pivotal trial will evaluate the efficacy and safety of oral nicotinamide versus placebo to prevent further keratinocyte carcinoma in 396 high-risk solid organ transplant recipients. Data from our previous internal pilot study (N=120 participants) will be combined with data from the current pivotal trial (N=276 additional patients) in the final analysis.

03

Conditions studied

  • Non-melanoma Skin Cancer
  • Carcinoma, Squamous Cell
  • Carcinoma, Basal Cell
  • Keratinocyte Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old
  • Kidney, liver, heart, or lung transplant at least two years ago
  • History of at least one prior -confirmed keratinocyte carcinoma or squamous cell carcinoma in situ
  • Currently with a calcineurin inhibitor-based regimen (cyclosporine or tacrolimus)
  • Able to attend follow-up visits

Exclusion criteria

Exclusion Criteria:

  • Use of nicotinamide or niacin (≥250 mg daily) within past 12 weeks
  • Untreated localized skin cancer at baseline (patient can enrol after skin cancer treatment)
  • -confirmed acute rejection episode within the past 12 weeks
  • Active liver disease (high >3 times or >1.5 times)
  • Severe kidney disease (estimated \<20 mL/min/1.73 m2)
  • Solid organ or hematologic , invasive melanoma, Merkel cell carcinoma, or skin cancer within the past five years
  • Pregnancy or lactation
  • Need for ongoing carbamazepine or primidone
  • Allergy to nicotinamide or any ingredient of the vitamin or placebo capsules
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
396 participants (estimated)

Study arms

  • Experimental
    Nicotinamide

    Intervention Drug : Nicotinamide

    Drug: Nicotinamide

  • Placebo comparator
    Placebo

    Intervention: Placebo Oral Capsule

    Drug: Placebo

Interventions

  • DrugNiacinamideStudies of NiacinamideNiacinamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral nicotinamide (500 mg) twice daily

    Also known as: niacinamide

  • DrugPlacebo

    Matching placebo capsule twice daily

06

What researchers measure

Primary outcomes

  1. Time to first biopsy-confirmed keratinocyte carcinoma (basal cell carcinoma or invasive cutaneous squamous cell carcinoma)

    Time frame: Up to 208 weeks

Secondary outcomes

  1. Time to first invasive squamous cell carcinoma during follow-up

    Time frame: Up to 208 weeks

  2. Time to first basal cell carcinoma during follow-up

    Time frame: Up to 208 weeks

  3. Time to multiple keratinocyte carcinomas over follow-up

    Time frame: Up to 208 weeks

  4. Occurrence of adverse events during follow-up

    Overall and by body system, frequency, seriousness, and severity

    Time frame: 208 weeks

  5. Acute graft rejection (biopsy-confirmed)

    Adverse event

    Time frame: 208 weeks

  6. Graft loss or retransplantation

    Adverse event

    Time frame: 208 weeks

  7. High/low cyclosporine or tacrolimus blood concentration requiring dose adjustment

    Adverse event

    Time frame: 208 weeks

  8. Change from baseline in annual Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) score

    Time frame: 52 weeks

  9. Change from baseline in annual Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) score

    Time frame: 104 weeks

  10. Change from baseline in annual Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) score

    Time frame: 156 weeks

  11. Change from baseline in annual Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) score

    Time frame: 208 weeks

  12. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Montreal Cognitive Assessment (MoCA)

    Time frame: 52 weeks

  13. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Montreal Cognitive Assessment (MoCA)

    Time frame: 104 weeks

  14. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Montreal Cognitive Assessment (MoCA)

    Time frame: 156 weeks

  15. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Montreal Cognitive Assessment (MoCA)

    Time frame: 208 weeks

  16. Neurocognitive substudy - Proportion of participants with cognitive impairment

    As defined by the International Cognition and Cancer Task Force (T scores ≥2 standard deviations below the normative population mean on a single test, or ≥1.5 standard deviations below the mean on at least two tests, or both)

    Time frame: 52 weeks

  17. Neurocognitive substudy - Proportion of participants with cognitive impairment

    As defined by the International Cognition and Cancer Task Force (T scores ≥2 standard deviations below the normative population mean on a single test, or ≥1.5 standard deviations below the mean on at least two tests, or both)

    Time frame: 104 weeks

  18. Neurocognitive substudy - Proportion of participants with cognitive impairment

    As defined by the International Cognition and Cancer Task Force (T scores ≥2 standard deviations below the normative population mean on a single test, or ≥1.5 standard deviations below the mean on at least two tests, or both)

    Time frame: 156 weeks

  19. Neurocognitive substudy - Proportion of participants with cognitive impairment

    As defined by the International Cognition and Cancer Task Force (T scores ≥2 standard deviations below the normative population mean on a single test, or ≥1.5 standard deviations below the mean on at least two tests, or both)

    Time frame: 208 weeks

  20. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Hopkins Verbal Learning Test - Revised

    Time frame: 52 weeks

  21. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Hopkins Verbal Learning Test - Revised

    Time frame: 104 weeks

  22. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Hopkins Verbal Learning Test - Revised

    Time frame: 156 weeks

  23. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Hopkins Verbal Learning Test - Revised

    Time frame: 208 weeks

  24. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Trail Making A and B

    Time frame: 52 weeks

  25. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Trail Making A and B

    Time frame: 104 weeks

  26. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Trail Making A and B

    Time frame: 156 weeks

  27. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Trail Making A and B

    Time frame: 208 weeks

  28. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Controlled Oral Word Association

    Time frame: 52 weeks

  29. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Controlled Oral Word Association

    Time frame: 104 weeks

  30. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Controlled Oral Word Association

    Time frame: 156 weeks

  31. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Controlled Oral Word Association

    Time frame: 208 weeks

  32. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Animal Naming Task

    Time frame: 52 weeks

  33. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Animal Naming Task

    Time frame: 104 weeks

  34. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Animal Naming Task

    Time frame: 156 weeks

  35. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Animal Naming Task

    Time frame: 208 weeks

  36. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Wechsler Adult Intelligence Scale-Fourth Edition-Canadian (WAIS-IV-CDN).

    Time frame: 52 weeks

  37. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Wechsler Adult Intelligence Scale-Fourth Edition-Canadian (WAIS-IV-CDN).

    Time frame: 104 weeks

  38. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Wechsler Adult Intelligence Scale-Fourth Edition-Canadian (WAIS-IV-CDN).

    Time frame: 156 weeks

  39. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Wechsler Adult Intelligence Scale-Fourth Edition-Canadian (WAIS-IV-CDN).

    Time frame: 208 weeks

  40. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Digit Span subtest

    Time frame: 52 weeks

  41. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Digit Span subtest

    Time frame: 104 weeks

  42. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Digit Span subtest

    Time frame: 156 weeks

  43. Neurocognitive substudy - Change from baseline in demographically-corrected T score for Digit Span subtest

    Time frame: 208 weeks

07

Study locations

6 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The trial protocol and statistical code will be shared upon request. Beyond 18 months after trial completion, the anonymized participant-level dataset will made available for sharing with external researchers upon approval of a reasonable study proposal describing the intended data usage.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Beyond 18 months after trial completion.

Access criteria: Data will be made available for sharing with external researchers upon approval of a well-defined study proposal that clearly outlines the intended use of the data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Aug 2027, 48 months after the start.

Of 21 phase 3 interventional studies under Carcinoma, Squamous Cell, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 91. This study's planned 48 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2023
First posted
Jul 21, 2023
StartActual
Aug 28, 2023
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, site details and index terms
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 3 other changes: verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05955924
Lead sponsor
Women's College Hospital
Collaborators
Canadian Institutes of Health Research (CIHR), University Health Network, Toronto, NOW Foods
Responsible party
Sponsor
First posted
Jul 21, 2023
Start date
Aug 28, 2023
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Stephanie Jewell, BSc. Hons
Contact
sprintr@wchospital.ca
416 351-3732 ext. 2706
An-Wen Chan
principal investigator · Women's College Hospital
Sang Joseph Kim
principal investigator · University Health Network, Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niacinamide

Start the discussion